Search
Pibrentasvir
go.drugbank.com/drugs/DB13878ApprovedInvestigationalIn clinical trials, this combination therapy achieved SVR12 rate, or undetectable Hepatitis C for twelve or more weeks after the end of treatment, of ≥93% across genotypes 1a, 2a, 3a, 4, 5 and 6 [L940] … These resistance-associated amino acid substitutions included Q30D/deletion, Y93D/H/N or H58D +Y93H in genotype 1a replicons, F28S + M31I or P29S + K30G in genotype 2a replicons, and Y93H in genotype 3a
Etelcalcetide
go.drugbank.com/drugs/DB12865ApprovedInvestigationalEtelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017. … Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis.
Alpelisib
go.drugbank.com/drugs/DB12015ApprovedInvestigational[L6652] In April 2022, the FDA granted the use of alpelisib in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS) in adults and children who require systemic therapy.[L41384] … Alpelisib was granted FDA approval on 24 May 2019.
Bentiromide
go.drugbank.com/drugs/DB00522ApprovedWithdrawnBentiromide is currently not available in the U.S. or Canada. … Bentiromide is a dipeptide that is used in the bentiromide test, which is a screening test for evaluating pancreatic exocrine function and monitoring the adequacy of supplemental pancreatic therapy.
Categories: Compounds used in a research, industrial, or household settingDacomitinib
go.drugbank.com/drugs/DB11963ApprovedInvestigational[L4810] Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ovarian cancer model[A39624], although further investigations are needed. … Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible
Tetradecyl hydrogen sulfate (ester)
go.drugbank.com/drugs/DB11328ApprovedSodium tetradecyl sulfate is an anionic surface-active agent which is used for its wetting properties in the industry and is also used in medicine as a blood vessel irritant and sclerosing agent for hemorrhoids … Sodium tetradecyl sulfate has been widely used since the 1950s, and in 1978 the first successful report of injecting a 1% solution into spider angiomas in 144 patients was made.
Rituximab
go.drugbank.com/drugs/DB00073ApprovedInvestigationalOn November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab) [L4808]. … Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes.
Nabumetone
go.drugbank.com/drugs/DB00461ApprovedNabumetone was developed by Smithkline Beecham under the trade name Relafen and first received FDA approval in December, 1991.[L6568] … [A179077] While slightly reduced, possibly due to a degree of cyclooxygenase-2 selectivity (COX-2), nabumetone still produces significant adverse effects in the GI tract.
Mixtures: NuDroxiPAK N-500Recombinant stabilized RSV B prefusion F antigen
go.drugbank.com/drugs/DB18714ApprovedInvestigational[L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023. … of an adjuvant.
Bordetella pertussis toxoid antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14388ApprovedInvestigationalBordetella pertussis toxoid antigen (formaldehyde inactivated) is a vaccine.
Mixtures: -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE, Repevax Injektionssuspension in einer Fertigspritze